Innovation and access to medical technologies: Challenges for middle income countries

Dr Manica Balasegaram
MSF Access Campaign - November 2014
MSF operates on the basis of population needs
Middle Income Countries (MICs)

Classifications
• 75% poorest live in MICs

• WB uses macro economic criteria, not public health or population socioeconomic data to classify

• Broad categorization of MICs (currently 100+ countries)

Consequences
• Loss of ODA and global health funding; ‘Graduation’ from GAVI & GF

• Tiered pricing leads to higher costs and exclusion from patent VLs and other LIC “access strategies”

• Pressure to adopt strict levels of IP protection (TRIPS Plus) and not use public health legal safeguards
Problem scenarios

- TPP: Enormous pressure placed on MICs to adopt strict / graduating IP rules that will increase cost medicines
- MICs may suffer disproportionate burden of disease e.g. TB
- MICs may fall behind in implementing Public Health strategies, including vaccination
- VLs: exclusion from licences e.g. HCV, including high burden countries
Introduction of PCV

Share of LICs and MICs that have introduced or plan to introduce PCV
In percentage of total number of LICs and MICs

37 LICs with data in 2012
100 MICs with data in 2012

- 0% in 2008
- 4% in 2009
- 9% in 2010
- 16% in 2011
- 27% in 2012
- 34% in 2013
- 32% in 2014
- 54% in 2015
- 55% in 2016

Low Income Countries (LIC) vs. Middle Income Countries (MIC)
Extent of MDR-TB burden

Percentage of new TB cases with multidrug-resistant tuberculosis*

* Figures are based on the most recent year for which data have been reported, which varies among countries.

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.


© WHO 2013. All rights reserved.
Opportunities to improve access

• Increased political collaboration between MICs; contribute and adapt global solidarity mechanisms

• MICs investing more in key areas of Public Health / HSS/ Regulatory

• MICs investing much more financial, scientific and political resources for needs driven innovation

• MICs promote new models of innovation to address areas of market failure / promote rationale use

• Broadening quality production of medicines and vaccines
3P Proposal: Push + Pull + Pool

OPEN COLLABORATIVE FRAMEWORK

POOL
Managed by: Medecines Patent Pool

Milestone prizes:
IND Phase IIB

PUSH

Hit to Lead
Lead Opt.
Pre-clinical Studies

Discovery
Later Stage Preclinical

GLP Tox Phase I Phase II

Clinical Development

Push fund phase III